Drug updated on 11/14/2023
|Capsule (oral: 100 mg)
|Ongoing and Completed Studies
- For treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).
- For treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
- For treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Product Monograph / Prescribing Information
|Gavreto (pralsetinib) Prescribing Information.
|Genentech, Inc., South San Francisco, CA
Systematic Reviews / Meta-Analyses
|Clinical, pharmacoeconomic, and stakeholder input combined report.
|Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review.
|Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer.
|Assessment report: Gavreto.
Clinical Practice Guidelines
|Therapy for stage iv non–small-cell lung cancer with driver alterations: ASCO living guideline.
|Journal of Clinical Oncology
|2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer.
|NCCN guidelines insights: non–small cell lung cancer, version 2.2021.
|Journal of the National Comprehensive Cancer Network
|Treating non-small cell lung cancer.
|American Cancer Society